http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10882821-B1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc2b03342511abc88f60c63f2acd96d0 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
filingDate | 2018-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1f1000da5fb55fc194b43f86b0bad02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bacf26db0542707ea22c0b7955214eb5 |
publicationDate | 2021-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-10882821-B1 |
titleOfInvention | Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes |
abstract | Aspects of the present disclosure include methods of reducing the deleterious impact of a target gene in a cell, such as the deleterious activity of a mutant extended nucleotide repeat (NR) containing target gene in a cell, by contacting the cell with an effective amount of an enantiomeric tetrahydrocarbazolamine compound. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended NR containing target gene may be reduced, e.g., by reducing (and in some instances differentially, including selectively, reducing) the production or activity of toxic expression products (e.g., RNA or protein) encoded by the target gene. Kits and compositions for practicing the subject methods are also provided. |
priorityDate | 2017-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 704.